Vital Signs: Future of Healthcare
Produced by Onyx, Published in Fortune
Dr. Adil Ali
Is a world without eyedrops possible?
SpyGlass Pharma is poised to revolutionize glaucoma treatment by implanting an innovative long-term drug delivery system directly inside the eye. Their treatment promises to continuously release eyedrop medication for 3 years after surgery, as opposed to using eye drops manually every day.
Blood tests for cancer are here and Guardant Health is leading the charge
Guardant Health has seen a string of consistent firsts - most recently FDA approval for colorectal cancer in July, 2024
GERD affects millions of Americans. This drug is the first major innovation in three decades.
GERD affects 65 million Americans, yet innovation in treatment had stagnated. Phathom Pharmaceuticals' FDA approval of VOQUEZNA® (vonoprazan) is a big moment for patients.
Let there Belite: an oral pill for vision loss
If left untreated, Stargardt disease and Geographic Atrophy almost always lead to vision loss and blindness - but a groundbreaking oral treatment in the last stage of clinical trials offers new hope.
How ImmunityBio is transforming cancer treatment - in just 30 seconds
“I think I'm blessed with truly the best team in all of pharma… we are doing something that's bigger than all of us!”
Ocugen has a cure in sight
“The cost of gene therapies can reach millions of dollars per patient… Our goal is developing cost-effective treatments that can be accessible globally.”
Gene therapy in ophthalmology is on the cusp of a breakthrough
"One of our first patients was treated over five years ago. He had received 109 injections over 10 years, and five years after a single Ixo-Vec injection, he is free of injections with stable vision and no fluid in the eye."
CAR T-cell therapies beat blood cancer - can they do the same for autoimmune diseases?
CAR T-cell therapies are often lauded as one of the industry’s most important frontiers, and these therapies have seen amazing success in treating hematological cancers — will autoimmune diseases yield next?
How Seer is using proteomics to revolutionize how we understand complex diseases
Seer's Proteograph Product and Analysis suites are utilizing proprietary nanoparticle technology to help us understand diseases like never before. David Horn, President and CFO, tells us more.
This biotech is using the chromatin regulatory system to fight back against cancer
Foghorn Therapeutics recently announced dosing of the first patient in the Phase 1 trial of FHD-909 in collaboration with Eli Lilly.
Cell therapy used to be expensive, then Fabian Gerlinghaus and the Cell Shuttle changed everything
The CEO of Cellares sits down to tell us how the Cell Shuttle, an engineering marvel of 21st Century biotech, was invented and the lives that it could save...
Alphabet's Verily is the future of precision and public health
We spoke with Stephen Gillett, Alphabet’s health-tech boss on life, leadership and AI.
A deep dive into one of the fastest growing biotechs of all time
Avidity Biosciences has achieved successful data readouts for all three of its programs in Phase 1/2 clinical trials, initiated its first Phase 3 trial, and raised over $1.1 billion this year.
Inside the world’s most innovative square mile: MassBio leads the life sciences
Kendalle Burlin O’Connell tells us about the privilege of heading up MassBio - the organization that represents the extraordinary life sciences sector in Massachusetts.
How rationally designed therapeutics could revolutionize gene therapy
Gene therapy holds incredible promise, but the challenge has always been delivery - Affinia Therapeutics seeks to solve one of the most important problems that the industry faces.